Published in Women's Health Weekly, December 6th, 2001
Under this partnership, InterMune has the responsibility for the clinical and regulatory development of interferon (gamma)-1b, and Boehringer Ingelheim retains an option to exclusively promote interferon (gamma)-1b under Boehringer Ingelheim's trade name, Imukin, in all countries outside of the United States, Canada and Japan. InterMune may opt to promote the product where Boehringer Ingelheim does not do so. The indications previously...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly